Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 3c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.03 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.4 million .

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• Kaiser Aluminum names Fred Stephan as CEO, effective November 2026
• Micron Technology (MU) call put ratio 1.4 calls to 1 put on 1.2M contracts as share price up 4%